Xlife Sciences AG

SWX:XLS Stock Report

Market Cap: CHF 119.4m

Xlife Sciences Valuation

Is XLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of XLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 30.01
Fair Value
30.7% undervalued intrinsic discount
0
Number of Analysts

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XLS?

Key metric:

The above table shows the Price to Earnings ratio for XLS. This is calculated by dividing XLS's market cap by their current earnings.
What is XLS's PE Ratio?
PE Ratio5.6x
EarningsCHF 21.24m
Market CapCHF 119.43m

Price to Earnings Ratio vs Peers

How does XLS's PE Ratio compare to its peers?

The above table shows the PE ratio for XLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.4x
SKAN SKAN Group
55x17.8%CHF 1.8b
TECN Tecan Group
29.9x13.9%CHF 3.0b
SFZN Siegfried Holding
34.2x13.0%CHF 4.4b
BANB Bachem Holding
38.6x17.8%CHF 4.4b
XLS Xlife Sciences
5.6xn/aCHF 119.4m

Price to Earnings Ratio vs Industry

How does XLS's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
XLS 5.6xIndustry Avg. 34.3xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price to Earnings Ratio vs Fair Ratio

What is XLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XLS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.6x
Fair PE Ration/a

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 12:52
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xlife Sciences AG is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel JelovcanStifel, Equities Research
Ulrich HuwaldWarburg Research GmbH